SCHEMBL7053321

SCHEMBL7053321

O=C(O)c1cc2cncc(Oc3ccc(Cl)cc3)c2s1

nearest known ligand 0.66

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 16/20 0.66
CCNC P24863 15/20 0.66
ICAM1 P05362 5/20 0.52
SELE P16581 5/20 0.52
VCAM1 P19320 4/20 0.52
CCNT1 O60563 2/20 0.52
CDK9 P50750 2/20 0.52
MAP3K8 P41279 2/20 0.50
PIM1 P11309 1/20 0.45
MAP2K2 P36507 1/20 0.45
MAP4K2 Q12851 1/20 0.45
SLC22A12 Q96S37 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7056134 0.89 ICAM1 (0.67) CDK8CCNCICAM1SELEVCAM1
SCHEMBL7051842 0.80 CDK8 (1.00) CDK8CCNCICAM1SELEVCAM1
SCHEMBL7056138 0.79 CDK8 (0.55) CDK8CCNCICAM1SELEVCAM1
SCHEMBL7055574 0.74 CCNC (0.47) CDK8CCNCICAM1SELEVCAM1
SCHEMBL7056641 0.73 CCNC (0.62) CDK8CCNCICAM1SELEVCAM1
SCHEMBL25948368 0.72 CCNC (0.56) CDK8CCNCICAM1SELEVCAM1
SCHEMBL7053673 0.71 CDK8 (0.46) CDK8CCNCICAM1SELEVCAM1
SCHEMBL7057140 0.69 CDK8 (1.00) CDK8CCNCICAM1SELEVCAM1
SCHEMBL17173219 0.68 P2RY14 (0.46) CDK8CCNCICAM1SELEVCAM1
SCHEMBL18105641 0.68 SLC22A12 (0.47) MAP3K8PIM1SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030220365-A1 Cell adhesion-inhibiting antiinflammatory compounds STEWART ANDREW O (US) 2003-11-27 US disclosed
US-6579882-B2 Thieno(2,3-d)pyrimidine derivatives ABBOTT LABORATORIES 2003-06-17 US disclosed
EP-1181296-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2002-02-27 EP disclosed
US-20010020030-A1 Cell adhesion-inhibiting antiinflammatory compounds ABBVIE INC. 2001-09-06 US disclosed
US-6232320-B1 THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES ABBOTT LABORATORIES 2001-05-15 US disclosed
EP-1090009-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2001-04-11 EP disclosed
WO-2000075145-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2000-12-14 WO disclosed
WO-1999062908-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 1999-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010020030-A1 Cell adhesion-inhibiting antiinflammatory compounds ICAM1, VCAM1, EPCAM CDK8 2986/4885CCNC 1780/4885ICAM1 1/4885
US-20030220365-A1 Cell adhesion-inhibiting antiinflammatory compounds ICAM1, VCAM1, EPCAM CDK8 2986/4885CCNC 1780/4885ICAM1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.